Cancer drugs boost AstraZeneca profits

Semafor

Lean Left

Factuality

Ownership

Cancer drugs boost AstraZeneca profits

The NewsAstraZeneca announced a 38% jump in annual pretax profits, driven by strong sales of its cancer and immunology treatments. Britain’s largest pharmaceutical firm reported last-quarter sales of $14.9 billion, beating expectations despite falling sales in China, which the company attributed to a mild winter in the country reducing demand for respiratory drugs. Cancer is a disease of aging, and as developed-world populations get older, diagn…

The Objective | Periodismo ethos

economiadigital.es

View article

Reposted by

economiadigital.es

Factuality

Ownership

AstraZeneca has closed 2024 with solid financial growth, consolidating its position as one of the leading companies in the pharmaceutical sector. Total revenues increased by 21% to reach $54,073 million, driven by an increase of 19% in the sales of its medicines, the continuous advance of the drugs in association (Alliance Revenue) and the achievement of sales-based milestones (Collaboration Revenue). This growth has been reflected in all its th…

BizToc

Factuality

Ownership

AstraZeneca reports strong results boosted by promising trials

AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of products.

The Motley Fool UK

Factuality

Ownership

Here's why AstraZeneca stock jumped nearly 6% in the FTSE 100 today

Today (6 February) was good for shareholders of AstraZeneca (LSE: AZN). The FTSE 100‘s largest company vaulted 5.9% higher to 11,786p after dropping a strong set of earnings. This helped push the Footsie up to 8,766, a record intraday high. Interest rates were also cut today, bringing down the cost of borrowing to 4.5%. So more gains could be ahead. I added to my holding in the pharma giant in early November when the stock dipped under 10,000p. …

Endpoints News

Factuality

Ownership

AstraZeneca offers some detail on China probe, reaffirms commitment to that market

LONDON — AstraZeneca on Thursday provided insight on an ongoing China probe into the company concerning alleged illegal drug imports, giving investors and analysts some reassurance on the pharma company’s future in that country. AstraZeneca revealed ...

perspectivemedia.com

Factuality

Ownership

AstraZeneca ‘very disappointed’ after ditching £450m Liverpool vaccine site

Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision. The boss of drugmaker AstraZeneca has said he was “very disappointed” with the firm’s move to scrap plans for a £450 million vaccine plant in Liverpool, but insisted the business case did not stack up. Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision, which it revealed earlier this week, saying…